Background/Aims: Unilateral ureteric obstruction (UUO) in neonatal rodents can be used as a paradigm for in utero obstruction in humans and a platform for studying the potential of novel therapies for congenital obstructive nephropathy. The present study examined the effect of rosuvastatin (Ros) on key morphometric measures of renal injury and corresponding gene expression correlates following neonatal UUO in the rat. Methods: Neonatal rats subjected to UUO and controls were treated daily with vehicle or Ros for 14 days. Quantification of tubular dilatation, glomerular size and number and tubulointerstitial fibrotic area was performed and changes validated by reference to appropriate renal gene expression correlates. Results: UUO increased tubular diameter and interstitial fibrosis by 2.7- and 7-fold, respectively, in parallel with increases in renal transforming growth factor-β1 (TGF-β1) and tumor necrosis factor-α (TNF-α) mRNA levels. Glomerular number and size were reduced by 52 and 33%, respectively. Reductions in WT-1 mRNA and protein expression were noted following obstruction occurring in tandem with reduced mRNA levels for BMP-7 and E-cadherin. Ros attenuated tubular dilatation (33%) and interstitial fibrosis (72%) in association with the normalization of renal TGF-β1 and TNF-α mRNA levels. Ros improved glomerular number and size (30 and 50%), and preserved mRNA and protein expression levels of WT-1 and normalized mRNA levels for BMP-7 and E-cadherin. Conclusions: Ros treatment attenuated all changes, most notably the increase in interstitial fibrosis. Notably, Ros treatment was unable to completely salvage glomerular development. Together these data highlight the therapeutic potential and limitations of Ros in neonatal obstruction.

Keywords:
Neonatal obstruction, UUO rosuvastatin, Fibrosis, Nephropathy
1.
Becker A, Baum M: Obstructive uropathy. Early Hum Dev 2006;82:15–22.
2.
Ahmadzadeh A, Tahmasebi M, Gharibvand MM: Causes and outcome of prenatally diagnosed hydronephrosis. Saudi J Kidney Dis Transpl 2009;20:246–250.
3.
Docherty NG, O’Sullivan OE, Healy DA, Fitzpatrick JM, Watson RW: Evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction. Am J Physiol Renal Physiol 2006;290:F4–F13.
4.
Power RE, Doyle BT, Higgins D, Brady HR, Fitzpatrick JM, Watson RW: Mechanical deformation induced apoptosis in human proximal renal tubular epithelial cells is caspase dependent. J Urol 2004;171:457–461.
5.
Cachat F, Lange-Sperandio B, Chang AY, Kiley SC, Thornhill BA, Forbes MS, Chevalier RL: Ureteral obstruction in neonatal mice elicits segment-specific tubular cell responses leading to nephron loss. Kidney Int 2003;63:564–575.
6.
Manucha W: Biochemical-molecular markers in unilateral ureteral obstruction. Biocell 2007;31:1–12.
7.
Dendooven A, Ishola DA Jr, Nguyen TQ, Van der Giezen DM, Kok RJ, Goldschmeding R, Joles JA: Oxidative stress in obstructive nephropathy. Int J Exp Pathol 2011;92:202–210.
8.
Manucha W, Carrizo L, Ruete C, Molina H, Vallés P: Angiotensin II type I antagonist on oxidative stress and heat shock protein 70 (HSP-70) expression in obstructive nephropathy. Cell Mol Biol (Noisy-le-grand) 2005;8;51:547–555.
9.
Manucha W, Carrizo L, Ruete C, Vallés PG: Apoptosis induction is associated with decreased NHE1 expression in neonatal unilateral ureteric obstruction. BJU Int 2007;100:191–198.
10.
Meldrum KK, Metcalfe P, Leslie JA, Misseri R, Hile KL, Meldrum DR: TNF-α neutralization decreases nuclear factor-ĸB activation and apoptosis during renal obstruction. J Surg Res 2006;131:182–188.
11.
Truong LD, Gaber L, Eknoyan G: Obstructive uropathy. Contrib Nephrol. Basel, Karger, 2011, vol 169, pp 311–326.
12.
Kones R: Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease: a perspective. Drug Des Devel Ther 2010;4:383–413.
13.
Mizuguchi Y, Miyajima A, Kosaka T, Asano T, Asano T, Hayakawa M: Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction. J Urol 2004;172:2456–2459.
14.
Vieira JM Jr, Mantovani E, Rodrigues LT, Dellê H, Noronha IL, Fujihara CK, Zatz R: Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol Dial Transplant 2005;20:1582–1591.
15.
Tian S, Ding G, Jia R, Chu G: Tubulointerstitial macrophage accumulation is regulated by sequentially expressed osteopontin and macrophage colony-stimulating factor: implication for the role of atorvastatin. Mediators Inflamm 2006;12919.
16.
Mazzei L, García IM, Cacciamani V, Benardón ME, Manucha W: WT-1 mRNA expression is modulated by nitric oxide availability and Hsp70 interaction after neonatal unilateral ureteral obstruction. Biocell 2010;34:121–132.
17.
Manucha W, Kurbán F, Mazzei L, Benardón ME, Bocanegra V, Tosi MR, Vallés P: eNOS/Hsp70 interaction on rosuvastatin cytoprotective effect in neonatal obstructive nephropathy. Eur J Pharmacol 2011;650:487–495.
18.
Manucha W, Vallés PG: Cytoprotective role of nitric oxide associated with Hsp70 expression in neonatal obstructive nephropathy. Nitric Oxide 2008;18:204–215.
19.
Morrissey J, Hruska K, Guo G, Wang S, Chen Q, Klahr S: Bone morphometric protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol 2002;13:S14–S21.
20.
Hruska KA, Guo G, Wozniak M, Martin D, Miller S, Liapis H, Loveday K, Klahr S, Sampath TK, Morrissey J: Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol (Renal Physiol) 2000;279:F130–F143.
21.
Ferder L, Inserra F, Romano L, Ercole L, Pszenny V: Decreased glomerulosclerosis in aging by angiotensin-converting enzyme inhibitors. J Am Soc Nephrol 1994;5:1147–1152.
22.
Pritchard-Jones K, Fleming S, Davidson D, Bickmore W, Porteousl D, Gosden C, Bard J, Buckler A, Pelletier J, Housman D, et al: The candidate Wilms’ tumour gene is involved in genitourinary development. Nature 1990;346:194–197.
23.
Hosono S, Gross I, English MA, Hajra KM, Fearon ER, Licht JD: E-cadherin is a WT-1 target gene. J Biol Chem 2000;275:10943–10953.
24.
Manson SR, Niederhoff RA, Hruska KA, Austin PF: The BMP-7-Smad1/5/8 pathway promotes kidney repair after obstruction induced renal injury. J Urol 2011;185(suppl): 2523–2530.
25.
Chevalier RL, Thornhill BA, Chang AY, Cachat F, Lackey A: Recovery from release of ureteral obstruction in the rat: relationship to nephrogenesis. Kidney Int 2002;61:2033–2043.
26.
Quaggin SE, Kreidberg JA: Development of the renal glomerulus: good neighbors and good fences. Development 2008;135:609–620.
27.
Ratliff B, Rodebaugh J, Sekulic M, Solhaug M: Glomerular eNOS gene expression during postnatal maturation and AT1 receptor inhibition. Pediatr Nephrol 2007;22:1135–1142.
28.
Ratliff B, Rodebaugh J, Sekulic M, Dong KW, Solhaug M: Nitric oxide synthase and renin-angiotensin gene expression and NOS function in the postnatal renal resistance vasculature. Pediatr Nephrol 2009;24:355–365.
29.
Kalaitzidis RG, Elisaf MS: The role of statins in chronic kidney disease. Am J Nephrol 2011;34:195–202.
30.
Campese VM, Park J: HMG-CoA reductase inhibitors and the kidney. Kidney Int 2007;71:1215–1222.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.